{"certainAgreement":{"otherDetails":"No unpublished information contained herein may be disclosed without prior written approval from AstraZeneca. Access to this document must be restricted to relevant parties. This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile observed to date. No safety concerns reported. Only Sub-study 1 Part A was started; Parts B \\& C were not started."},"pointOfContact":{"email":"information.center@astrazeneca.com","organization":"AstraZeneca","phone":"1-877-240-9479","title":"Global Clinical Lead"}}